AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China Study builds on positive Phase 2a […]
First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces […]
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]
“Go west, young man!” Such was the famous advice of Horace Greeley, founder and editor of the (long defunct) New York Tribune, to an acquaintance, Josiah B. Grinnell, in the mid-19th century. Countless individuals, businesses, and industries have since followed that advice – and gone on to strike gold. But when it comes to where […]
· Increasing momentum as we expanded our portfolio of investments, built the team and fostered new partnerships · Three new portfolio company investments and two existing portfolio company financing extensions · First ever Novo Nordisk and Novo Holdings Partnering Day focusing on Cardio Metabolic disease Copenhagen, Denmark, 3 April 2024 – Novo Holdings Asia Investments team today publishes its […]
